| Quality assessment | No of patients | Effect | Quality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Docetaxel | Control | Relative (95% CI) | Absolute | |
| Overall survival | |||||||||||
| 21 | observational studies | none | none | serious2 | serious5 | none | N=102 | - | Median OS =9 and 7.3 months | ⊕○○○ VERY LOW | |
| Progression-free survival | |||||||||||
| 13 | observational studies | none | none | serious2 | serious5 | none | N=72 | - | Median PFS = 1.58 months | ⊕○○○ VERY LOW | |
| Overall tumour response | |||||||||||
| 21 | observational studies | none | none | serious2 | serious5 | none | 12/102 (11.8%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Neutropenia (assessed with: NCI-CTC) | |||||||||||
| 21 | observational studies | none | none | serious2 | serious5 | none | 35/102 (34.3%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Thrombocytopenia (assessed with: NCI-CTC) | |||||||||||
| 14 | observational studies | none | none | serious2 | serious5 | none | 1/30 (3.3%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Anaemia (assessed with: NCI-CTC) | |||||||||||
| 2 | observational studies | none | none | serious2 | serious5 | none | 9/102 (8.8%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Leucopenia | |||||||||||
| 0 | No evidence available | ||||||||||
| Treatment-related mortality | |||||||||||
| 13 | observational studies | none | none | serious2 | serious5 | none | 0/72 (0%) | - | - | - | ⊕○○○ VERY LOW |
| Health-related quality of life | |||||||||||
| 0 | No evidence available | ||||||||||
Neoadjuvant and adjuvant chemotherapy considered as first-line chemotherapy in both studies
Small sample size/low number of events limits the precision of this outcome
From: 5, Managing locally advanced or metastatic bladder cancer
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.